Keywords
References
-
1.
Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311(22):2315-25. [PubMed ID: 24915263]. https://doi.org/10.1001/jama.2014.5951.
-
2.
Abdi H, Azizi F, Amouzegar A. Insulin monotherapy versus insulin combined with other glucose-lowering agents in type 2 diabetes: A narrative review. Int J Endocrinol Metab. 2018;16(2). e65600. [PubMed ID: 30008760]. [PubMed Central ID: PMC6035366]. https://doi.org/10.5812/ijem.65600.
-
3.
Davidson MB. Insulin analogs--is there a compelling case to use them? No!. Diabetes Care. 2014;37(6):1771-4. [PubMed ID: 24855160]. [PubMed Central ID: PMC4030087]. https://doi.org/10.2337/dc13-2915.
-
4.
Grunberger G. Insulin analogs-are they worth it? Yes!. Diabetes Care. 2014;37(6):1767-70. [PubMed ID: 24855159]. https://doi.org/10.2337/dc14-0031.
-
5.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90-S102. [PubMed ID: 30559235]. https://doi.org/10.2337/dc19-S009.
-
6.
Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: Synopsis of the world health organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med. 2018;169(6):394-7. [PubMed ID: 30178023]. https://doi.org/10.7326/M18-1149.
-
7.
Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2). CD005613. [PubMed ID: 17443605]. https://doi.org/10.1002/14651858.CD005613.pub3.
-
8.
Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczynski G, Lis J, Syta A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015;52(4):649-62. [PubMed ID: 25585592]. [PubMed Central ID: PMC4506471]. https://doi.org/10.1007/s00592-014-0698-4.
-
9.
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018;12. CD013228. [PubMed ID: 30556900]. [PubMed Central ID: PMC6517032]. https://doi.org/10.1002/14651858.CD013228.
-
10.
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;(6). CD012161. [PubMed ID: 27362975]. [PubMed Central ID: PMC6597145]. https://doi.org/10.1002/14651858.CD012161.
-
11.
Luo J, Khan NF, Manetti T, Rose J, Kaloghlian A, Gadhe B, et al. Implementation of a health plan program for switching from analogue to human insulin and glycemic control among medicare beneficiaries with type 2 diabetes. JAMA. 2019;321(4):374-84. [PubMed ID: 30694321]. [PubMed Central ID: PMC6439763]. https://doi.org/10.1001/jama.2018.21364.
-
12.
Lipska KJ. Insulin analogues for type 2 diabetes. JAMA. 2019;321(4):350-1. [PubMed ID: 30694303]. https://doi.org/10.1001/jama.2018.21356.